{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Steroid&page=24", "query": { "intervention": "Steroid", "page": 24 }, "page_size": 10 }, "pagination": { "page": 24, "page_size": 10, "total_count": 6275, "total_pages": 628, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Steroid&page=25&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Steroid&page=23&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-07T05:30:41.490Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04231435", "title": "Influence of Fedratinib on the Pharmacokinetics of the Transporter Probe Substrates Digoxin, Rosuvastatin, and Metformin", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteers" ], "interventions": [ { "name": "Fedratinib", "type": "DRUG" }, { "name": "Digoxin", "type": "DRUG" }, { "name": "Rosuvastatin", "type": "DRUG" }, { "name": "Metformin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 24, "start_date": "2019-12-18", "completion_date": "2020-02-21", "has_results": false, "last_update_posted_date": "2020-05-21", "last_synced_at": "2026-11-07T05:30:41.490Z", "location_count": 1, "location_summary": "Austin, Texas", "locations": [ { "city": "Austin", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04231435" }, { "nct_id": "NCT01084525", "title": "OTO-104 for Meniere's Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Meniere's Disease" ], "interventions": [ { "name": "OTO-104 (steroid) 3 mg", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "OTO-104 (steroid) 12 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Otonomy, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 44, "start_date": "2010-03", "completion_date": "2011-04", "has_results": false, "last_update_posted_date": "2011-06-08", "last_synced_at": "2026-11-07T05:30:41.490Z", "location_count": 15, "location_summary": "Los Angeles, California • San Diego, California • Colorado Springs, Colorado + 12 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Colorado Springs", "state": "Colorado" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01084525" }, { "nct_id": "NCT00133991", "title": "Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia", "Lymphoma" ], "interventions": [ { "name": "Filgrastim", "type": "BIOLOGICAL" }, { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Hydrocortisone", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "30 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "30 Years to 120 Years" }, "enrollment_count": 23, "start_date": "2005-07", "completion_date": "2013-08", "has_results": true, "last_update_posted_date": "2018-09-17", "last_synced_at": "2026-11-07T05:30:41.490Z", "location_count": 2, "location_summary": "Baltimore, Maryland • Philadelphia, Pennsylvania", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00133991" }, { "nct_id": "NCT00343460", "title": "APF530 or Aloxi (Palonosetron Hydrochloride) Combined With Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Nausea and Vomiting", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "APF530", "type": "DRUG" }, { "name": "dexamethasone", "type": "DRUG" }, { "name": "Palonosetron Hydrochloride", "type": "DRUG" }, { "name": "placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Heron Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 1428, "start_date": "2006-06", "completion_date": "2009-02", "has_results": true, "last_update_posted_date": "2026-03-02", "last_synced_at": "2026-11-07T05:30:41.490Z", "location_count": 52, "location_summary": "Anniston, Alabama • Glendale, Arizona • Tucson, Arizona + 46 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00343460" }, { "nct_id": "NCT00304018", "title": "Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes" ], "interventions": [ { "name": "anti-thymocyte globulin", "type": "BIOLOGICAL" }, { "name": "sargramostim", "type": "BIOLOGICAL" }, { "name": "busulfan", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "fludarabine phosphate", "type": "DRUG" }, { "name": "prednisone", "type": "DRUG" }, { "name": "tacrolimus", "type": "DRUG" }, { "name": "allogeneic hematopoietic stem cell transplantation", "type": "PROCEDURE" }, { "name": "umbilical cord blood transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 5, "start_date": "2002-10", "completion_date": "2009-03", "has_results": false, "last_update_posted_date": "2013-08-14", "last_synced_at": "2026-11-07T05:30:41.490Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00304018" }, { "nct_id": "NCT03827018", "title": "KPL-301 for Subjects With Giant Cell Arteritis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Giant Cell Arteritis" ], "interventions": [ { "name": "mavrilimumab", "type": "COMBINATION_PRODUCT" }, { "name": "placebo", "type": "COMBINATION_PRODUCT" }, { "name": "prednisone", "type": "DRUG" } ], "intervention_types": [ "COMBINATION_PRODUCT", "DRUG" ], "sponsor": "Kiniksa Pharmaceuticals, Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "50 Years to 85 Years" }, "enrollment_count": 70, "start_date": "2018-09-20", "completion_date": "2020-11-25", "has_results": true, "last_update_posted_date": "2023-10-23", "last_synced_at": "2026-11-07T05:30:41.490Z", "location_count": 8, "location_summary": "Sarasota, Florida • Tampa, Florida • Atlanta, Georgia + 5 more", "locations": [ { "city": "Sarasota", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Lansing", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT03827018" }, { "nct_id": "NCT00132925", "title": "An Efficacy and Safety Evaluation of Nasacort AQ in Children Ages 2-5 Years With Perennial Allergic Rhinitis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Rhinitis, Allergic, Perennial" ], "interventions": [ { "name": "Triamcinolone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "5 Years", "sex": "ALL", "summary": "2 Years to 5 Years" }, "enrollment_count": 460, "start_date": "2003-11", "completion_date": "2006-02", "has_results": false, "last_update_posted_date": "2011-01-11", "last_synced_at": "2026-11-07T05:30:41.490Z", "location_count": 1, "location_summary": "Bridgewater, New Jersey", "locations": [ { "city": "Bridgewater", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00132925" }, { "nct_id": "NCT04521140", "title": "Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt, Following Corneal Transplant Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Corneal Edema", "Corneal Defect", "Corneal Transplant", "Penetrating KeratoPlasty", "Anterior Chamber Inflammation", "Ocular Pain", "Intraocular Pressure" ], "interventions": [ { "name": "Dextenza 0.4Mg Ophthalmic Insert", "type": "DRUG" }, { "name": "Prednisolone Acetate 1% Oph Susp", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Nicole Fram M.D.", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2020-10-16", "completion_date": "2023-01-04", "has_results": false, "last_update_posted_date": "2023-07-24", "last_synced_at": "2026-11-07T05:30:41.490Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04521140" }, { "nct_id": "NCT03459040", "title": "A Proof of Concept Pilot Trial of Alpha-1-Antitrypsin for Pre-Emption Of Steroid-Refractory Acute GVHD", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Graft-versus-host-disease", "GVHD" ], "interventions": [ { "name": "Alpha 1-Antitrypsin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "John Levine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2018-08-17", "completion_date": "2020-08-21", "has_results": true, "last_update_posted_date": "2021-07-12", "last_synced_at": "2026-11-07T05:30:41.490Z", "location_count": 5, "location_summary": "Duarte, California • Boston, Massachusetts • New York, New York + 2 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" }, { "city": "Columbus", "state": "Ohio" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT03459040" }, { "nct_id": "NCT01576718", "title": "A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler (Puffer) in Adolescents and Adults Who Have Asthma That is Not Controlled by High Dose Inhaled Corticosteroid Asthma Medications", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Asthma" ], "interventions": [ { "name": "Fp MDPI", "type": "DRUG" }, { "name": "Placebo MDPI", "type": "OTHER" }, { "name": "Flovent Diskus", "type": "DRUG" }, { "name": "albuterol/salbutamol", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Teva Branded Pharmaceutical Products R&D, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 889, "start_date": "2012-04", "completion_date": "2013-10", "has_results": true, "last_update_posted_date": "2018-05-08", "last_synced_at": "2026-11-07T05:30:41.490Z", "location_count": 148, "location_summary": "Birmingham, Alabama • Homewood, Alabama • Goodyear, Arizona + 114 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Homewood", "state": "Alabama" }, { "city": "Goodyear", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Bakersfield", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01576718" } ] }